N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Does Additional Use of Preoperative Azithromycin Decrease Posthysterectomy Infections

Sponsor: Helsinki University Central Hospital • ClinicalTrials.gov ID: NCT05337566

Registry updated: 2026-09-22
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

During hysterectomy bacteria may enter into the peritoneal cavity through vaginal opening and contaminate the healing tissues. The risk for deep infection after hysterectomy is about 5%. By reducing post-hysterectomy infections, it is possible to reduce individual burden of disease in addition to the direct and indirect financial costs. This study primary aim is to assess if prophylactic preoperative use of azithromycin in addition to generally used cefuroxime decreases post-hysterectomy infections as compared to cefuroxime only prophylaxis during 30 days after hysterectomy. Secondary aim is to assess if there is change in post-hysterectomy superficial infections, urinary tract infections, or post-operative fever between the cohorts and to report possible side-effects of the used antibiotics. In addition, the study finds out a possible role of bacterial vaginosis and microbiome n post-hysterectomy infections.

Interventions

  • Azithromycin Pill + Cefuroxime (Drug)
    Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
  • Placebo + Cefuroxime (Drug)
    Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision

Eligibility criteria

Inclusion Criteria: * Women undergoing hysterectomy for benign indication in University Hospitals (Helsinki University Hospital, Turku University Hospital, Tampere University Hospital, Oulu University Hospital and Kuopio University Hospital) who have not any contraindications for azithromycin or cefuroxime. Exclusion Criteria: * Inability to understand the study protocol. * Allergy for either cefuroxime or azithromycin. * Congenital or acquired prolonged Q-T-corrected interval. All the participants will be asked about arrhythmias and whether they have congenital arrhythmias in the family, * Electrocardiogram will be checked for all the participants. * Use of medicines that may prolong Q-T-corrected interval (class Ia arrhythmia medications, quinidine, procainamide, and class III arrhythmia medications dofetilide, amiodarone and sotalol). * Use of selective serotonin reuptake inhibitor medication and prolonged Q-T-corrected interval.

Conditions

Infection Post Op Hysterectomy Antibiotics Prophylactic

Locations

  • Helsinki University Central Hospital — Helsinki, Finland
  • Jyväskylä Central Hospital — Jyväskylä, Finland
  • Kuopio University Central Hospital — Kuopio, Finland
  • Oulu University Central Hospital — Oulu, Finland
  • Tampere University Central Hospital — Tampere, Finland
  • Turku University Central Hospital — Turku, Finland
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record